RESUMO
OBJECTIVE: Recent research has suggested that mental health is not only the absence of mental illness but includes aspects of well-being. One common psychological assessment used to assess dimensions of well-being is the Mental Health Continuum-Short Form (MHC-SF). The MHC-SF is a 14-item measure that assesses emotional, psychological, and social well-being. The purpose of this study was to assess measurement invariance of the MHC-SF across US military veterans and civilians. METHOD: First, we examined the factor structure of the MHC-SF separately for veterans (n = 418) and civilians (n = 411). We then conducted multiple group confirmatory factor analysis (MG-CFA) to assess measurement invariance for the two groups. RESULTS: Findings suggested there were three latent factors representing emotional, social, and psychological well-being. Results from MG-CFA suggested that the MHC-SF is invariant across veterans and civilians. CONCLUSION: Researchers and practitioners can administer the MHC-SF with both groups.
Assuntos
Transtornos Mentais , Veteranos , Humanos , Adulto , Saúde Mental , Psicometria , Satisfação Pessoal , Análise Fatorial , Reprodutibilidade dos TestesRESUMO
Treatments of obesity and type II diabetes target often gene functions involved in appetite-satiety, fat and carbohydrate metabolism or thermogenesis. None of these, have provided efficient drug therapy due to a large number of genes involved in weight and energy management, the redundancy of biochemical pathways and the environmental factors. Here I discuss a new approach based on studies of genes/proteins that are associated with human "lean or starvation" phenotype that became very rare in the course of evolution. This approach has led to the identification of the congenital enteropeptidase deficiency gene and the Anderson's Disease gene as a potential targets for obesity and type II diabetes treatment. The advantages of these targets are: 1) they are expressed exclusively in the intestine; 2) they are peripheral targets as opposed to systemic targets; 3) they are not redundant targets. These targets open new hopes for the development of novel drugs for the treatment of common metabolic syndrome.
Assuntos
Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/metabolismo , Obesidade/genética , Obesidade/metabolismo , Doenças Raras/genética , Doenças Raras/metabolismo , Inanição/genética , Inanição/metabolismo , Evolução Biológica , Enteropeptidase/deficiência , Enteropeptidase/genética , Humanos , Síndrome Metabólica , Erros Inatos do Metabolismo/genéticaRESUMO
In the search of new strategies to fight against obesity, we targeted a gene pathway involved in energy uptake. We have thus investigated the APOB mRNA editing protein (APOBEC1) gene pathway that is involved in fat absorption in the intestine. The APOB gene encodes two proteins, APOB100 and APOB48, via the editing of a single nucleotide in the APOB mRNA by the APOBEC1 enzyme. The APOB48 protein is mandatory for the synthesis of chylomicrons by intestinal cells to transport dietary lipids and cholesterol. We produced transgenic rabbits expressing permanently and ubiquitously a small hairpin RNA targeting the rabbit APOBEC1 mRNA. These rabbits exhibited a moderately but significantly reduced level of APOBEC1 gene expression in the intestine, a reduced level of editing of the APOB mRNA, a reduced level of synthesis of chylomicrons after a food challenge, a reduced total mass of body lipids and finally presented a sustained lean phenotype without any obvious physiological disorder. Interestingly, no compensatory mechanism opposed to the phenotype. These lean transgenic rabbits were crossed with transgenic rabbits expressing in the intestine the human APOBEC1 gene. Double transgenic animals did not present any lean phenotype, thus proving that the intestinal expression of the human APOBEC1 transgene was able to counterbalance the reduction of the rabbit APOBEC1 gene expression. Thus, a moderate reduction of the APOBEC1 dependent editing induces a lean phenotype at least in the rabbit species. This suggests that the APOBEC1 gene might be a novel target for obesity treatment.
Assuntos
Citidina Desaminase/genética , Expressão Gênica , Técnicas de Silenciamento de Genes , Interferência de RNA , Redução de Peso , Desaminase APOBEC-1 , Animais , Animais Geneticamente Modificados , Apolipoproteína B-48/sangue , Sequência de Bases , Colesterol/sangue , Dieta Hiperlipídica , Humanos , Mucosa Intestinal/metabolismo , Fígado/metabolismo , Dados de Sequência Molecular , Fenótipo , Edição de RNA/genética , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , RNA Interferente Pequeno/metabolismo , Coelhos , Transgenes , Triglicerídeos/sangueRESUMO
BACKGROUND: Obesity research focuses essentially on gene targets associated with the obese phenotype. None of these targets have yet provided a viable drug therapy. Focusing instead on genes that are involved in energy absorption and that are associated with a "human starvation phenotype", we have identified enteropeptidase (EP), a gene associated with congenital enteropeptidase deficiency, as a novel target for obesity treatment. The advantages of this target are that the gene is expressed exclusively in the brush border of the intestine; it is peripheral and not redundant. METHODOLOGY/PRINCIPAL FINDINGS: Potent and selective EP inhibitors were designed around a boroarginine or borolysine motif. Oral administration of these compounds to mice restricted the bioavailability of dietary energy, and in a long-term treatment it significantly diminished the rate of increase in body weight, despite ad libitum food intake. No adverse reactions of the type seen with lipase inhibitors, such as diarrhea or steatorrhea, were observed. This validates EP as a novel, druggable target for obesity treatment. CONCLUSIONS: In vivo testing of novel boroarginine or borolysine-based EP inhibitors validates a novel approach to the treatment of obesity.
Assuntos
Enteropeptidase/genética , Obesidade/genética , Obesidade/patologia , Inanição/metabolismo , Administração Oral , Motivos de Aminoácidos , Animais , Arginina/química , Disponibilidade Biológica , Peso Corporal , Relação Dose-Resposta a Droga , Desenho de Fármacos , Ingestão de Alimentos , Enteropeptidase/metabolismo , Enteropeptidase/fisiologia , Comportamento Alimentar , Humanos , Lisina/química , Camundongos , Microvilosidades/metabolismo , Modelos Químicos , Modelos Genéticos , Fenótipo , Triglicerídeos/metabolismoRESUMO
Several hundred genes associated or linked to obesity have been described in the scientific literature. Whereas many of these genes are potential targets for the treatment of obesity and associated conditions, none of them have permitted the developement of an efficient drug therapy. As proposed by the 'thrifty genotype' theory, obesity genes may have conferred an evolutionary advantage in times of food shortage through efficient energy exploitation, while 'lean' or 'energy expenditure' genes may have become very rare during the same periods. It is therefore a challenge to identify 'energy expenditure genes' or 'energy absorption genes,' whose mutations or single nucleotide polymorphisms do result in reduced energy intake. We submit that such 'energy absorption' or 'energy expenditure' genes (crucial genes) are potential new targets for the treatment of obesity. These genes can be identified in rare genetic diseases that produce a lean, failure-to-thrive, energy malabsorption or starvation phenotype.